

## MolMed appoints new Director of Drug Development

Milan (Italy), 15 September 2008 - MolMed S.p.A. (Milan:MLM) is pleased to announce that Dr. Raul Ziliotto joined the Company today as Drug Development Director. Dr. Ziliotto will bring MolMed a wealth of expertise in drug development, as he contributed significantly to development, scale-up and pharmaceutical industrialisation processes in leading multinational Groups.

"Dr. Ziliotto's vast experience, entirely focused on biological and biotech-based drugs, will allow us to further intensify and accelerate the full development of our most advanced candidate drugs, TK cell therapy in Phase III for the cure of high-risk leukaemias, and NGR-hTNF, MolMed's vascular targeting agent currently in Phase II in different types of solid tumours", commented Claudio Bordignon, President and CEO of MolMed.

Dr. Ziliotto started his career at Farmitalia Carlo Erba as a Researcher in R&D, then moved on to cover positions of increasing responsibility and acquiring a broad experience in Research, Development and Production of biological drugs. In 1995 he became Director of Biological Products Development and responsible for Validation of several fermentation plants and macrolaboratories for chemical synthesis at Pharmacia, and subsequently at Pharmacia-Upjohn, Pfizer and Nerviano Medical Sciences. His most recent experience was in Farmaopera, where he was responsible for research and development of biological processes, scaling up fermentation processes and downstreaming.

### About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel antitumour therapies. MolMed's pipeline includes three novel therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in Phase III in high-risk acute leukaemias; ARENEGYR, a novel vascular targeting agent (VTA), in Phase II in four different indications (colorectal, small-cell lung and liver cancers, and mesothelioma); and M3TK, a therapeutic vaccine, in Phase I/II in advanced melanoma. MolMed's clinical pipeline is supported by a broad portfolio of therapeutic candidates. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The company's shares (Milan:MLM) are listed at the Milan Stock Exchange, on the Standard segment (class I) of the MTA managed by Borsa Italiana.

### For further information, please contact:

Holger Neecke  
*Director Business Development - Investor Relator*  
MolMed S.p.A.  
phone: +39 02 21277.205  
fax: +39 02 21277.325  
e-mail: [investor.relations@molmed.com](mailto:investor.relations@molmed.com)

Elena Lungagnani  
*Communication Manager*  
MolMed S.p.A.  
phone: +39 02 21277.207  
fax: +39 02 21277.325  
e-mail: [media.relations@molmed.com](mailto:media.relations@molmed.com)